48 research outputs found
Reposicionamiento de drogas efectos de la combinación de metformina y propanolol sobre modelos de cáncer colorrectal
El reposicionamiento de drogas en oncología se refiere al uso de fármacos originalmente formulados para otras indicaciones que mostraron potencial antitumoral. En este trabajo, se seleccionó un grupo de drogas en reposicionamiento que incluyen metformina (M, utilizada en el tratamiento de la diabetes), propranolol (P, indicado para tratar la hipertensión), cloroquina (CQ, se usa en el tratamiento o prevención de la malaria), DHEA (un precursor de hormonas sexuales), orlistat (empleado en el tratamiento de la obesidad), atorvastatina (utilizado para tratar niveles altos de colesterol) y dicloroacetato (un inhibidor de la piruvato deshidrogenasa cinasa). El potencial antitumoral de estos fármacos se evaluó in vitro en células de cáncer de colon humano HCT116 y HT29 a través de ensayos de viabilidad estándar, individualmente o de forma combinada. Todos los fármacos probados inhibieron significativamente la proliferación de células HCT116 y HT29 de una manera dependiente de la dosis. De las combinaciones probadas, M+P resultó la más atractiva en ambas líneas celulares, ya que mostró una fuerte inhibición del crecimiento incluso combinando dosis bajas de ambos fármacos (P <0,001). Adicionalmente, el tratamiento mostro efectos significativos tanto sobre la capacidad migratoria celular, aumentando el número de adhesiones focales en células tratadas, como en los niveles de apoptosis que también se vieron incrementados por el tratamiento. Los datos preliminares de un modelo in vivo con ratones BALB/c bajo un protocolo de carcinogénesis estándar de azoximetano (carcinógeno iniciador)/sulfato de dextrano (agente promotor) indicaron un beneficio potencial de la combinación M+P en la prevención del desarrollo de tumores de colon, sin síntomas asociados de toxicidad. A través de la tinción inmunohistoquímica para el antígeno Ki67 se detectó un menor número de células proliferativas en tumores tratados, lo que confirmó el efecto del tratamiento in vivo. En conjunto, nuestros resultados sugieren que la terapia con medicamentos reposicionados podría ser de interés para el tratamiento del cáncer de colon y, en particular, la combinación de M+P podría inhibir su desarrollo y potencialmente el desarrollo de metástasisFil: Anselmino L.E..
Universidad Nacional de RosarioFil: Baglioni M.V..
Universidad Nacional de RosarioFil: Rico M.J..
Universidad Nacional de RosarioFil: Rozados V.R..
Universidad Nacional de RosarioFil: Scharovsky O.G..
Universidad Nacional de RosarioFil: Fernández C.O..
Universidad Nacional de RosarioFil: Martínez-Marignac V..
Universidad Nacional de RosarioFil: Menacho-Márquez M..
Universidad Nacional de Rosari
Identification of proximal SUMO-dependent interactors using SUMO-ID
[EN]The fast dynamics and reversibility of posttranslational modifications by the ubiquitin family pose significant challenges for research. Here we present SUMO-ID, a technology that merges proximity biotinylation by TurboID and protein-fragment complementation to find SUMO-dependent interactors of proteins of interest. We develop an optimized split-TurboID version and show SUMO interaction-dependent labelling of proteins proximal to PML and RANGAP1. SUMO-dependent interactors of PML are involved in transcription, DNA damage, stress response and SUMO modification and are highly enriched in SUMO Interacting Motifs, but may only represent a subset of the total PML proximal proteome. Likewise, SUMO-ID also allow us to identify interactors of SUMOylated SALL1, a less characterized SUMO substrate. Furthermore, using TP53 as a substrate, we identify SUMO1, SUMO2 and Ubiquitin preferential interactors. Thus, SUMO-ID is a powerful tool that allows to study the consequences of SUMO-dependent interactions, and may further unravel the complexity of the ubiquitin code.We are thankful to Iraide Escobes for her work in the Proteomics Platform at CIC bioGUNE and Arnoud de Ru in the Center for Proteomics and Metabolomics at the LUMC. O.B.-G., F.T., R.B. and A.C.O.V. acknowledge funding by the grant 765445-EU (UbiCODE Program). R.B. acknowledges funding by grants BFU2017-84653-P and PID2020-114178GB-I00 (MINECO/FEDER, EU), SEV-2016-0644 (Severo Ochoa Excellence Program), SAF2017-90900-REDT (UBIRed Program) and IT1165-19 (Basque Country Government). Additional support was provided by the Department of Industry, Tourism, and Trade of the Basque Country Government (Elkartek Research Programs) and by the Innovation Technology Department of the Bizkaia County. VM acknowledges FPI grant PRE2018-086230 (MINECO/FEDER, EU). F.E. is at Proteomics Platform, member of ProteoRed-ISCIII (PT13/0001/0027). F.E. and A.M.A. acknowledge CIBERehd. A.C. acknowledges the Basque Department of education (IKERTALDE IT1106-16), the MCIU (PID2019-108787RB-I00 (FEDER/EU), Severo Ochoa Excellence Accreditation SEV-2016-0644, Excellence Networks RED2018-102769-T), the AECC (GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17, and the European Research Council (Starting Grant 336343, PoC 754627, Consolidator grant 819242). CIBERONC was co-funded with FEDER funds. U.M. acknowledges the Basque Government Department of Education (IT1165-19) and the Spanish MCIU (SAF2016-76898-P (FEDER/EU))
Evidence for muon neutrino oscillation in an accelerator-based experiment
We present results for muon neutrino oscillation in the KEK to Kamioka (K2K)
long-baseline neutrino oscillation experiment. K2K uses an accelerator-produced
muon neutrino beam with a mean energy of 1.3 GeV directed at the
Super-Kamiokande detector. We observed the energy dependent disappearance of
muon neutrino, which we presume have oscillated to tau neutrino. The
probability that we would observe these results if there is no neutrino
oscillation is 0.0050% (4.0 sigma).Comment: 5 pages, 4 figure
Anisotropy studies around the galactic centre at EeV energies with the Auger Observatory
Data from the Pierre Auger Observatory are analyzed to search for
anisotropies near the direction of the Galactic Centre at EeV energies. The
exposure of the surface array in this part of the sky is already significantly
larger than that of the fore-runner experiments. Our results do not support
previous findings of localized excesses in the AGASA and SUGAR data. We set an
upper bound on a point-like flux of cosmic rays arriving from the Galactic
Centre which excludes several scenarios predicting sources of EeV neutrons from
Sagittarius . Also the events detected simultaneously by the surface and
fluorescence detectors (the `hybrid' data set), which have better pointing
accuracy but are less numerous than those of the surface array alone, do not
show any significant localized excess from this direction.Comment: Matches published versio
Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry
Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID- 19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7-160) vs. 49.3 (16-109) mg/dL; p < 0.001), ferritin (791 (393-1534) vs. 470 (236- 996) µg/dL; p < 0.001), D dimer (750 (430-1400) vs. 617 (345-1180) µg/dL; p < 0.001), and lower Sp02/Fi02 (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%. Conclusions: Patients with greater comorbidity, severity, and inflammatory markers were those treated with CTs. In severe patients, there is a trend towards the use of higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%
Anti- Sporothrix spp. activity of medicinal plants
ABSTRACT Cases of sporotrichosis in humans and animals without satisfactory clinical response have increased, a warning sign of strains resistant to conventional antifungal agents. The urgent search for alternative therapies was an incentive for research on medicinal plants with anti-Sporothrix spp. properties. A bibliographic survey was performed based on scientific papers about in vitro and in vivo antifungal activity of essential oils and extracts of plants in differents solvents against the fungal of the Sporothrix schenckii complex. The study methodology consisted of a literature review in Google Scholar, Science Direct, Pubmed, Bireme and Springer link with papers from 1986 to 2015. We found 141 species of plants that were investigated, of which 100 species were concentrated in 39 botanical families that had confirmed anti-Sporothrix activity. Combretaceae, Asteraceae and Lamiaceae represented the botanical families with the greatest number of plants species with antifungal potential, using different methodologies. However, there are few studies with medicinal plants in experimental infection in animals that prove their activity in the treatment of sporotrichosis. It reinforces the need for further research related to standardization of in vitro methodologies and in vivo studies related to safety and to toxicity potential of these plants with anti-Sporothrix spp. activity
Repositioning of the global epicentre of non-optimal cholesterol
High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol—which is a marker of cardiovascular risk—changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million–4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.</p
Charged-particle nuclear modification factors in PbPb and pPb collisions at √=sNN=5.02 TeV
The spectra of charged particles produced within the pseudorapidity window
|η| < 1 at √
sNN = 5.02 TeV are measured using 404 µb
−1 of PbPb and 27.4 pb−1 of pp data
collected by the CMS detector at the LHC in 2015. The spectra are presented over the
transverse momentum ranges spanning 0.5 < pT < 400 GeV in pp and 0.7 < pT < 400 GeV
in PbPb collisions. The corresponding nuclear modification factor, RAA, is measured in
bins of collision centrality. The RAA in the 5% most central collisions shows a maximal
suppression by a factor of 7–8 in the pT region of 6–9 GeV. This dip is followed by an increase,
which continues up to the highest pT measured, and approaches unity in the vicinity
of pT = 200 GeV. The RAA is compared to theoretical predictions and earlier experimental
results at lower collision energies. The newly measured pp spectrum is combined with the
pPb spectrum previously published by the CMS collaboration to construct the pPb nuclear
modification factor, RpA, up to 120 GeV. For pT > 20 GeV, RpA exhibits weak momentum
dependence and shows a moderate enhancement above unity
Oracion funebre en las exequias que a expensas de la devocion de muchos consagro el Reverendo Clero de San Salvador de Valencia en su Iglesia à 2 de julio 1696 a la memoria de la Venerable Madre Sor Josepha Maria de Santa Ines (en el siglo Josepha Albiñana) Religiosa Agustina Descalza ... de la villa de Beniganim / dixola el Doctor D. Ioseph Fernandez de Marmanillo ... de la Congregacion de el Oratorio de San Felipe Neri ... ; dala a la estampa la misma devocion.
REBIUN8403818La h. de grab. calc., retrato de la biografiad